Biogen reports Leqembi Alzheimer's drug sales reached $96M in Q1, up from $19M last year, with $52M from US market. Eisai ...

Stately Bio has raised a $12 million seed round led by AIX Ventures to advance machine learning techniques that recognize ...

Amicus pays Dimerix $30M upfront for US rights to DMX-200, a late-stage FSGS therapy, with potential milestone payments of ...

Moderna is expanding a cost control program as it seeks to break even in the coming years, despite challenges for vaccine ...

Teladoc has bought virtual therapy startup UpLift to sell mental health treatment, including treatment from its ...

A tribunal within the US Patent and Trademark Office invalidated several claims of a patent held by AbbVie’s Pharmacyclics, ...

Regeneron can’t dodge a lawsuit alleging it unlawfully inflated Medicare reimbursements for its eye drug Eylea and defrauded ...

Top cancer scientists, former NIH leaders, and patient advocates warned that the Trump administration's cuts to science ...

GSK said its decoupling with Haleon is a key reason why it views itself as “well-positioned” in the face of potential ...

BridgeBio's Attruby exceeds Q1 forecasts with $36.7M in sales, 2,072 prescriptions. CEO Neil Kumar credits clinical data; ...

Merck is shifting manufacturing for its blockbuster drug Keytruda to a new $1 billion factory in Delaware, doubling down on ...

Pfizer CEO Albert Bourla gave an optimistic read on Tuesday when asked how he thought the trade levies might be implemented.